Gynecologic Cancers: Recent Episodes
ReachMD
Host: Warner K. Huh, MD
Guest: Kimberly Levinson, MD, MPH
More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.
Host: Pranshu Mohindra, MD
Guest: Melissa Teply, MD
Guest: Judith Paice, PhD, RN
Guest: Fionnuala Crowley, MD
This enduring program of the live-virtual symposium will focus on the challenges of managing cancer pain using the Evolve KOL Knockout™ case-based format. The key opinion leaders (KOLs) will be challenged by the host/moderator to diagnose and manage patient scenarios with varying levels of difficulty. Learners will vote on the winner of each case presentation round and the moderator will declare a match winner at the conclusion.
There will be learning, laughter, and only one KOL left standing!
Host: Warner K. Huh, MD
Guest: Sarah E. Dilley, MD, MPH, FACOG
Effective triage tests are needed to lessen diagnostic uncertainty when assessing cervical cancer risk and selecting which patients will move on to colposcopy. An FDA-approved dual-staining cytology test is available that can help in decision-making for a wide range of patients. Join Drs. Warner Huh and Sarah Dilley as they address current 2019 ASCCP guidelines and anticipate potential updates to ASCCP’s guidance in 2023.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Explore the case of a young patient to see the ACS and ASCCP cervical cancer screening guidelines in action. Who needs to be screened, how is it best to screen, and what's the best test? Leading experts, Drs. Leigh Cantrell and Warner Huh, review the benefits of primary screening as they explore shifts in current guidelines. Find out how you can improve outcomes for patients, not only through appropriate primary HPV testing in lieu of cytology as the screening modality, but also by reinforcing how a “negative” HPV test actually sends a powerful “positive” message. As a bonus, you might just change a young patient’s life.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Guest: Mark H. Stoler, MD
Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.
Host: Floor J. Backes, MD
Follow along as Dr. Floortje Backes walks us through a patient case and demonstrates the shared decision-making process of selecting an appropriate maintenance treatment regimen for advanced ovarian cancer.
Host: Lauren Ritterhouse, MD ,PhD
Guest: Pasi Antero Jänne, MD, PhD
Guest: Kanwal Raghav, MD
HER3 is the new marker on the block, but is it diagnostic, predictive, or prognostic? Hear from the experts, Drs. Lauren Ritterhouse, Pasi Jänne, and Kanwal Raghav, as they explore the role of HER3 in oncogenesis and resistance to EGFR TKIs. Find out how we can now target HER3 signaling in metastatic solid tumors through the use of emerging HER3-targeted therapies along with novel and exciting antibody-drug conjugate studies and strategies.
*Since the recording of this activity, clinical trial NCT04479436, patritumab deruxtecan in colorectal cancer, has been terminated early. To learn more about this trial, search for NCT04479436 on ClinicalTrials.gov.
Host: Mark Socinski, MD
Guest: Edward B. Garon, MD, MS
In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don’t have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.
Host: Mark Socinski, MD
Guest: John V. Heymach, MD, PhD
FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!
Host: Richard T. Penson, MD, MRCP
Guest: Ana Oaknin, MD
Therapeutic choices for many women with advanced endometrial cancer are being driven by our understanding of the mismatch repair (deficient/proficient) and microsatellite (instable/stable) status of their tumors. Join us as Dr. Richard Penson and Dr. Ana Oaknin discuss the global perspective surrounding the recent emergence of immunotherapy agents in the management of recurrent or metastatic endometrial cancer. Find out how to manage the toxicities of these newer therapies and discover just how critical a role molecular testing plays in selecting which patients receive a particular therapeutic strategy.
Host: Richard T. Penson, MD, MRCP
Guest: Nicoletta Colombo, MD
Guest: Christine Ghione
Therapeutic options are changing for many patients with advanced endometrial cancer. Join us as Dr. Richard Penson and Dr. Nicoletta Colombo discuss new immunotherapeutic approaches and the importance of a patient’s tumor genomic profile when determining which interventional strategy, they receive. Also hear from Ms. Christine Ghione, a patient advocate, who provides a firsthand perspective of shared decision-making and how the process may be improved.
Since the production of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.
Host: Floor J. Backes, MD
Guest: Robert L. Coleman, MD, FACOG, FACS
Does immunotherapy play a role in improving quality of life and survival for patients with ovarian cancer? Learn how experts are determining immunotherapy’s place in the treatment plan during the PARP era and what’s on the horizon.
Host: Charles E. Geyer, Jr., MD, FACP
Guest: Hope S. Rugo, MD
Although outcomes have improved for women with HER2-positive early-stage breast cancer, patients who do not have a pathologic complete response after neoadjuvant therapy are at an increased risk for recurrence and need further improvements in therapy options.
In this activity, Drs. Charles Geyer and Hope Rugo discuss how the management of HER2-positive early-stage breast cancer has evolved, the continued quest to reduce the burden of therapy on patients—and how subcutaneous approaches are achieving this—and other challenges in the treatment continuum.